Influence of nutritional deficiency on prognosis of renal cell carcinoma (RCC)

被引:39
|
作者
Ko, Kyungtae [1 ]
Park, Young H. [1 ]
Lee, Jeong W. [1 ]
Ku, Ja H. [1 ]
Kwak, Cheol [1 ]
Kim, Hyeon H. [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Urol, Seoul, South Korea
关键词
nutritional status; renal cell carcinoma; prognosis; body mass index; albumin; cholesterol; BODY-MASS INDEX; PRETREATMENT SERUM-ALBUMIN; FATTY-ACID SYNTHASE; INDEPENDENT PREDICTOR; COLORECTAL-CANCER; PANCREATIC-CANCER; KIDNEY CANCER; WEIGHT-LOSS; SURVIVAL; RISK;
D O I
10.1111/bju.12275
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To evaluate the prognosis of patients with renal cell carcinoma (RCC) by nutritional status defined by body mass index (BMI), serum albumin and cholesterol. Patients and Methods This study retrospectively enrolled 1437 patients who underwent radical nephrectomy (932) or partial nephrectomy (505) for RCC. We assigned nutritional status according to the presence of none or one nutritional risk factor (control group) and two or all three of the following nutritional risk factors (nutritional deficiency group). The nutritional factors and thresholds were preoperative albumin level (< 3.5 g/dL), preoperative cholesterol level (< 220 mg/dL), and preoperative BMI (< 23 kg/m(2)) Results The patients' mean (sd) age was 55.23 (12.41) years and BMI was 24.36 (3.17) kg/m(2). The mean (sd) serum cholesterol level was 180.07 (38.24) mg/dL, and the albumin level was 4.2 (0.45) g/dL. In all, 141 (9.8%) patients had none of the nutritional deficiency criteria, 802 (55.8%) had one, 429 (29.9%) had two, and 65 (4.5%) had all three. Clinicopathological variables, i.e. female gender, high tumour stage, positive lymph node metastasis, positive distant metastasis, high nuclear grade and non-clear cell type histopathology were associated with the nutritional deficiency group. In multivariate Cox analysis, nutritional deficiency was an independent predictor for RCC recurrence (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.05-1.83, P = 0.020) and RCC-related mortality (HR 2.06, 95% CI 1.39-3.03, P < 0.001). Conclusion Nutritional deficiency defined by BMI, serum albumin and cholesterol is an important factor that predicts postoperative prognosis of patients with RCC who have undergone radical or partial nephrectomy.
引用
收藏
页码:775 / 780
页数:6
相关论文
共 50 条
  • [41] mTOR Pathway Alterations in Chromophobe Renal Cell Carcinoma (RCC)
    Albadine, R.
    Schultz, L.
    Hicks, J.
    Demarzo, A. M.
    Argani, P.
    Carducci, M.
    Pili, R.
    Netto, G. J.
    LABORATORY INVESTIGATION, 2010, 90 : 174A - 174A
  • [42] Value of tumor nephrectomy in metastatic renal cell carcinoma (RCC)
    Scheepe, JR
    Mickisch, GH
    UROLOGE A, 2002, 41 (03): : 221 - 224
  • [43] THERAPY OF LOCALLY METASTASIZED RENAL-CELL CARCINOMA (RCC)
    KRAMER, W
    KLAN, R
    JONAS, D
    JOURNAL OF UROLOGY, 1987, 137 (04): : A333 - A333
  • [44] Medullary renal cell carcinoma (RCC): genomics and treatment outcomes
    Lee, Chung-Han
    Carlo, Maria
    Chen, Yingbei
    Chaim, Joshua
    Coskey, Devyn
    Woo, Kaitlin
    Voss, Martin
    Hsieh, James
    Feldman, Darren
    Motzer, Robert
    BJU INTERNATIONAL, 2016, 118 : 6 - 7
  • [45] Adjuvant therapy in renal cell carcinoma (RCC): progress, at last
    Bueno, Andrew N.
    Stein, Mark N.
    Runcie, Karie
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6448 - 6462
  • [46] Renal cell carcinoma (RCC) and telomerase activity: relationship to stage
    Mekhail, TM
    Kawanishi-Tabata, R
    Tubbs, R
    Novick, A
    Elson, P
    Ganapathi, R
    Ganapathi, M
    Bukowski, R
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2003, 21 (06) : 424 - 430
  • [47] Medullary renal cell carcinoma (RCC): Genomics and treatment outcomes
    Carlo, Maria Isabel
    Chen, Yingbei
    Chaim, Joshua
    Coskey, Devyn Taylor
    Woo, Kaitlin
    Hsieh, James
    Voss, Martin Henner
    Feldman, Darren R.
    Motzer, Robert J.
    Lee, Chung-Han
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC).
    Bukowski, R. M.
    Kabbinavar, F.
    Figlin, R. A.
    Flaherty, K.
    Srinivas, S.
    Vaishampayan, U.
    Drabkin, H.
    Dutcher, J.
    Scappaticci, F.
    McDermott, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 222S - 222S
  • [49] Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus?
    Thiel, David D.
    Lohse, Christine M.
    Arnold, Michelle L.
    Cheville, John C.
    Leibovich, Bradley C.
    Parker, Alexander S.
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (04) : 1005 - 1012
  • [50] Does left side renal cell carcinoma (RCC) with renal vein/vena cava thrombus predict worse prognosis than equivalent right side RCC tumor thrombus?
    David D. Thiel
    Christine M. Lohse
    Michelle L. Arnold
    John C. Cheville
    Bradley C. Leibovich
    Alexander S. Parker
    International Urology and Nephrology, 2012, 44 : 1005 - 1012